




## STICs and STONES: OV.24

A randomized phase II double-blind placebo-controlled trial of Acetylsalicylic acid (ASA) in chemoprevention of ovarian cancer in women with *BRCA1/2* mutations/Group name and number



### Stratification

- Age (<40 vs 40-50 vs >50)
- Current (last dose <6 mths) combined oral contraceptive use (Yes vs No)
- BRCA status (BRCA1 vs BRCA2)

**Co Chairs:** Oza A – Lheureux S  
**Pathology Chair:** Patricia Shaw  
**Senior Investigator:** Wendy Parulekar  
**Statistician:** Dongsheng Tu  
**Study coordinator:** WenLing Liu  
**Sponsor:** CCTG

**Grant Support:** CCSRI: Hecht Foundation: CCTG: PM Cancer Foundation:

**Drug Supply:** Apotex

### GCIG Groups:

ANZGOG: K. Phillips  
 ISGO: J. Korach, D. Tsoref  
 NCRI: R. Manchanda

## OV.24 / CCTG

---

**Trial setting:** Women with germline *BRCA1/2* mutations scheduled to undergo risk reducing surgery within 6 months to 2 years

**Study Design:** Randomized 2:1, double-blind, placebo controlled phase II

**Sponsor(s):** CCTG, ANZGOG

**Planned No. of patients:** 414


**Current accrual:** Commencing Fall 2017 in Canada and Australia

**Other important information:** Study has been submitted to Health Canada as pre-Clinical Trials Application. Pending further communication with regulatory authorities

# **SUPPLEMENTAL SLIDES**



## OV.24 / CCTG



### Stratification

- Age (<40 vs 40-50 vs >50)
- Current (last dose <6 mths) combined oral contraceptive use (Yes vs No)
- BRCA status (BRCA1 vs BRCA2)

- 
- Secondary
    - To assess Patient Acceptance of Intervention of Chemoprevention Studies in this High-risk Female Cohort
  - Tertiary
    - To characterize the Effect of Aspirin on HGSOC Tumourigenesis
      - Link between Tumourigenesis and Microenvironment
    - Hormone stimulation
    - Inflammatory cell phenotype
    - Markers of inflammation and oncogenic pathway expression
  - Biobanking for future correlative studies